Skip to main content
SpringerLink
Log in

Idarubicin preferred to daunorubicin as AML induction therapy

  • Newsletter Article
  • Published:
Inpharma Weekly

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Idarubicin preferred to daunorubicin as AML induction therapy. Inpharma Wkly. 1167, 19 (1998). https://doi.org/10.2165/00128413-199811670-00035

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199811670-00035

Keywords

Search

Navigation